Moderna Competitors and Similar CompaniesClear all
Moderna's competitors and similar companies include CureVac and Alnylam.
 Moderna Moderna (formerly Moderna Therapeutics) is a biotechnology company focused on messenger RNA (mRNA) medicine. |  Alnylam Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments. | ||
Founding Date | Founding Date 2010 | Founding Date 2000 | Founding Date 2002 |
Type | Type Public | Type Public | Type Public |
Tags | |||
Locations | Locations Tübingen, DE HQ Ottignies Louvain La Neuve, BE Wiesbaden, DE Amsterdam, NL Basel, CH Boston, US | ||
Employees | Employees 5,60044% increase | Employees 999 | Employees 1,32324% increase |
Valuation ($) | Valuation ($) 21.2 b | Valuation ($) 648.3 m | Valuation ($) 36.5 b |
Financial | |||
Revenue (est.) | Revenue (est.) $3.2b (FY, 2024) | Revenue (est.) €53.8m (FY, 2023) | Revenue (est.) $2.2b (FY, 2024) |
Cost of goods | Cost of goods $1.5b (FY, 2024) | Cost of goods €64.3m (FY, 2023) | Cost of goods $306.5m (FY, 2024) |
Gross profit | Gross profit $1.8b (FY, 2024) | Gross profit (€2.6m) (FY, 2023) | Gross profit $1.9b (FY, 2024) |
Net income | Net income ($3.6b) (FY, 2024) | Net income (€260.2m) (FY, 2023) | Net income ($278.2m) (FY, 2024) |
Operating ⚠ | |||
Patent Applications | Patent Applications 430 (FY, 2021) | Patent Applications 500 (Mar, 2020) | Patent Applications N/A |
Patents Issued | Patents Issued 270 (FY, 2020) | Patents Issued 233 (May, 2020) | Patents Issued N/A |
Funding | |||
Total funding raised | Total funding raised $ 1.8b | Total funding raised $ 1.1b | Total funding raised $ 1.5b |
For sources of this data, please see the company profile
View Company Profiles
CureVac
HQ
Tübingen, DE
Employees
999
CureVac is a biotechnology company offering messenger RNA (mRNA) technology.
View companyAlnylam
HQ
Cambridge, US
Employees
1,323↑ 24% increase
Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments.
View company